Cantor Fitzgerald initiated coverage on shares of Apnimed (NASDAQ:APMD – Free Report) in a research note published on Tuesday morning, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $60.00 target price on the stock.
Separately, Wall Street Zen raised shares of Apnimed to a “hold” rating in a research note on Saturday, August 8th. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $50.33.
Read Our Latest Analysis on APMD
Apnimed Trading Down 2.9%
Insider Activity at Apnimed
In related news, major shareholder Morningside Venture Investment acquired 312,500 shares of the stock in a transaction dated Monday, August 3rd. The shares were acquired at an average price of $16.00 per share, with a total value of $5,000,000.00. Following the acquisition, the insider owned 7,152,713 shares in the company, valued at approximately $114,443,408. The trade was a 4.57% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.
About Apnimed
Apnimed Inc is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies which address the neurobiology of sleep-related breathing diseases. Apnimed Inc is based in CAMBRIDGE, Mass.
See Also
- Five stocks we like better than Apnimed
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Apnimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apnimed and related companies with MarketBeat.com's FREE daily email newsletter.
